This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

8 Big Acquirers of 2011

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2. Sanofi (SNY - Get Report) is a diversified pharmaceutical company.

In April, Sanofi completed the acquisition of Genzyme Corp., a biotechnology company, for a total consideration of $19.6 billion, or $74.00 per share, in cash plus contingent value right (CVR), according to data compiled by Bloomberg.

The acquisition is expected to be accretive to Sanofi's business net earnings per share in the first year following closing, and accretive to business net earnings per share in the range of 98 cents to $1.30 by 2013. The deal will expand SNY's footprint in biotechnology and accelerate revenue growth.

For the third quarter, total sales were reported at $11.4 billion, up 4.58% compared to the 2010 quarter. Genzyme's sales were $1.0 billion, rising 6.9% from the corresponding quarter of 2010, or 8.7% of total sales.

Of the five analysts covering the stock, three rate it a buy and two rate a hold. Analysts polled by Bloomberg on average expect the stock to gain an average of 21% to $43.72 in the coming 12 months.

2 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ANR $0.51 0.00%
DHR $86.90 0.00%
ECL $115.06 0.00%
ESRX $86.00 0.00%
ESV $23.40 0.00%

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs